About: The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma
Creator	Del Rincón, Sonia Miller, Wilson Moussa, Omar Prabhu, Sathyen
Source	PMC
abstract	Melanoma is a type of skin cancer that originates in the pigment-producing cells of the body known as melanocytes. Most genetic aberrations in melanoma result in hyperactivation of the mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. We and others have shown that a specific protein synthesis pathway known as the MNK1/2-eIF4E axis is often dysregulated in cancer. The MNK1/2-eIF4E axis is a point of convergence for these signaling pathways that are commonly constitutively activated in melanoma. In this review we consider the functional implications of aberrant mRNA translation in melanoma and other malignancies. Moreover, we discuss the consequences of inhibiting the MNK1/2-eIF4E axis on the tumor and tumor-associated cells, and we provide important avenues for the utilization of this treatment modality in combination with other targeted and immune-based therapies. The past decade has seen the increased development of selective inhibitors to block the action of the MNK1/2-eIF4E pathway, which are predicted to be an effective therapy regardless of the melanoma subtype (e.g., cutaneous, acral, and mucosal).
has issue date	2020-06-05(xsd:dateTime)
bibo:doi	10.3390/ijms21114055
bibo:pmid	32517051
has license	cc-by
sha1sum (hex)	c816b013710e3b5bc4da57305b8754566708ee73
schema:url	https://doi.org/10.3390/ijms21114055
resource representing a document's title	The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma
has PubMed Central identifier	PMC7312468
has PubMed identifier	32517051
schema:publication	Int J Mol Sci
resource representing a document's body	covid:c816b013710e3b5bc4da57305b8754566708ee73#body_text
is schema:about of	named entity 'signaling pathways' named entity 'effective' named entity 'inhibitors' named entity 'implications' named entity 'mitogen' named entity 'tumor' named entity 'aberrations' named entity 'functional' named entity 'eIF4E' named entity 'Molecular' named entity 'Melanoma' named entity 'Axis' named entity 'specific' named entity 'protein kinase' named entity 'eIF4E' named entity 'hyperactivation' named entity 'MAPK' named entity 'Melanoma' named entity 'mRNA translation' named entity 'malignancies' named entity 'PI3K' named entity 'melanoma' named entity 'treatment modality' named entity 'pigment-producing cells' named entity 'protein synthesis' named entity 'MAPK' named entity 'tumor' named entity 'melanoma' named entity 'skin cancer' named entity 'eIF4A' named entity 'dasatinib' named entity 'neoplasia' named entity 'progression-free survival' named entity 'PDCD4' named entity 'MCL1' named entity 'multidrug resistance protein' named entity '4EGI-1' named entity 'tryptamine' named entity 'mRNA' named entity 'phosphorylation' named entity 'immunohistochemistry' named entity '4EGI-1' named entity 'mRNA translation' named entity 'melanoma' named entity 'PTEN' named entity 'prostate' named entity 'xenografts' named entity 'mTOR' named entity 'phase I clinical trials' named entity 'miRNA' named entity 'mRNA translation' named entity 'cellular transformation' named entity 'eIF4E' named entity 'nasopharyngeal carcinoma' named entity '4E-BP' named entity 'genetically engineered' named entity 'phase II clinical trial' named entity 'IL-17' named entity 'eIF4E' named entity 'NRAS' named entity 'malignancies' named entity 'tumor growth' named entity 'melanoma' named entity 'melanoma cells' named entity 'AML' named entity 'PI3K/Akt/mTOR' named entity 'mRNA translation' named entity 'miR' named entity 'small molecule inhibitors' named entity 'DEAD-box' named entity 'melanocytes' named entity 'HER2' named entity 'phosphorylation' named entity 'phosphorylation' named entity 'melanomas' named entity 'N-termini' named entity 'tumor necrosis factor α' named entity 'mTOR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software